Pace begins trials of cardiac diagnostic
This article was originally published in Clinica
Executive Summary
Canadian diagnostic manufacturer Pace is beginning trials of an ELISA to measure glycogen phosphorylase (GPBB) this month. The earliest known marker detectable in blood following ischaemic damage, GPBB indicates acute myocardial infarction or unstable angina. Patients are being enrolled at three hospitals - one in Canada and two in the US. Pace plans to file a 510(k) for the laboratory test with the US FDA in April.